Assessment of the influence of severe renal impairment on the pharmacokinetics of mirodenafil in Korean male volunteers
- Document Type
- Publications · Journal Article
- Registered DB
- SCIEScopus
- Journal Ranking
- JCR Q4Scopus Q2
- Journal
- INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS50(12) · pp.880 · 2012
- Citation
- Web of Science 3
- JCR IF
- JCR 2011 1.183
- ISSN
- 0946-1965
Authors
- Noh, Yook-HwanFirst authorDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
- Lim, Hyeong-SeokDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
- Cho, Sang-HeonDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
- Ghim, Jong-LyulDepartment of Clinical Pharmacology, Busan Paik Hospital, South Korea
- Choe, SangminClinical Trials Center, Pusan National University Hospital, South Korea
- Jung, Jin AhDepartment of Clinical Pharmacology and Therapeutics, Samsung Medical Center, South Korea
- Kim, Mi JoDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
- Kim, Yo HanDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
- Jin, Seok-JoonDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
- Kim, Soon BaeDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
- Park, Jung SikDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
- Lee, Sang KooDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
- Yang, Won SeokDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
- Chang, Jai WonDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
- Lee, BongyongLife Science RandD Center, SK Chemical Co. Ltd., South Korea
- Bae, Kyun-SeopCorresponding authorDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
Abstract
Objective: To evaluate and compare the pharmacokinetics and tolerability of a single oral dose of mirodenafil in volunteer patients with severe renal impairment and healthy volunteers. Methods and materials: This open-label, single-dose, parallel-group clinical study enrolled a total 12 volunteers (6 healthy volunteers and 6 volunteer patients with severe renal impairment). Each volunteer was orally administered 50 mg mirodenafil and serial blood samples were obtained after drug administration to determine the plasma concentration of mirodenafil using LC-MS/MS. The measured individual plasma concentrations were used to calculate the pharmacokinetic parameters using noncompartmental methods. Tolerability was also assessed using measurements of vital signs, clinical chemistry tests, and interviews. Results: All of the volunteers completed the study with no serious adverse events (AEs). A total of 4 AEs were reported, but all were of mild or moderate intensity and not considered to be related to the study drug. The geometric mean (95% CI) of the terminal half-life (t(1/2 beta)) and the apparent clearance (CL/F) values of mirodenafil were 2.2 (1.4 - 3.4) hours and 127.2 (95.1 - 170.2) 1/h in the volunteer patients, and 3.0 (2.1 - 4.4) hours and 136.1 (74.4 - 249.2) 1/h in the healthy volunteers, respectively. The geometric mean of the AUC(0-t) of the volunteer patients was 8% higher and the geometric mean for clearance was 7% lower compared with the healthy volunteers. However, the geometric mean of the C-max of the volunteer patients was 38% higher than that of the healthy volunteers. Conclusions: A single oral 50-mg dose of mirodenafil was well tolerated. Exposure (AUC(0-t)) to mirodenafil was similar in both healthy volunteers and volunteer patients with severe renal impairment and healthy volunteers.
Keywords
mirodenafilphosphodiesterase 5 (PDE5) inhibitorrenal impairmentpharmacokineticshealthy volunteersERECTILE DYSFUNCTION5 INHIBITORSK3530EFFICACYSAFETYMEN
Identifiers
- WoS UID
- 000313595100005



Login
Back to Publication list